Innovent and HUTCHMED Jointly Announce NDA Acceptance for Sintilimab and Fruquintinib
Innovent Biologics, Inc. (HKEX: 01801), a prominent biopharmaceutical company specializing in developing and marketing quality medicines for various diseases, is excited to share the great news regarding their recent submission with HUTCHMED (Nasdaq/AIM:HCM; HKEX:13). The New Drug Application (NDA) for the combination of sintilimab and fruquintinib aimed at treating advanced renal cell carcinoma (RCC) has been accepted for review by the China National Medical Products Administration.
Significance of the NDA Submission
This NDA is bolstered by findings from the FRUSICA-2 study, which was a randomized, open-label registration trial assessing the safety and efficacy of fruquintinib in conjunction with sintilimab against typical monotherapy treatments. Key results indicated that the therapy could potentially enhance progression-free survival (PFS) among patients. This combination not only met its main goals but also showed promising secondary outcomes such as improved response rates.
Insights from Innovent Leadership
Dr. Hui Zhou, Senior Vice President at Innovent, emphasized the importance of this NDA, stating that it represents a major stride in offering effective treatment alternatives for patients struggling with advanced RCC. With the integration of sintilimab, also recognized as TYVYT, this marks its tenth indication, highlighting a critical accomplishment in advancing cancer therapy.
Focus on Renal Cell Carcinoma
Renal cell carcinoma continues to be a significant health concern, particularly for patients who have exhausted first-line treatments. HUTCHMED’s Chief Medical Officer, Dr. Michael Shi, stated that addressing these gaps in treatment is a priority, ensuring patients have access to essential therapy options. The combination therapy submitted in this NDA is seen as a crucial step in tackling the needs within this patient population.
Future Directions with Sintilimab
Sintilimab, marketed as TYVYT, has become an integral part of cancer treatment regimens in China. The drug has received approval for multiple cancer indications and is included in the updated National Reimbursement Drug List, showcasing its accessibility to patients in need. Additionally, sintilimab has recently received conditional approval for its use in conjunction with fruquintinib for specific endometrial cancer cases, reflecting its versatility.
About Fruquintinib and its Role in Targeted Therapy
Fruquintinib stands out as a powerful oral agent targeting vascular endothelial growth factor receptors—an essential function in inhibiting tumor growth. Approved under the brand name ELUNATE, it offers hope for colorectal cancer patients and is indicative of a broader trend towards combination therapies in oncology, which allow for maximizing patient benefits through synergistic action.
Innovent's Commitment to Improving Patient Outcomes
With a rich portfolio of innovative pharmaceuticals and numerous candidates in various stages of clinical development, Innovent is poised to make significant contributions to cancer therapy. The company is dedicated to enhancing access to high-quality treatments, ensuring that patients worldwide receive the care they deserve. They also maintain partnerships with over 30 healthcare organizations to extend their research and development capabilities.
Frequently Asked Questions
What is the main focus of the NDA recently accepted?
The NDA is for the combination treatment of sintilimab and fruquintinib aimed at advanced renal cell carcinoma.
Why is the FRUSICA-2 study important?
This study provided pivotal data supporting the efficacy and safety of the drug combination, indicating improvements in progression-free survival.
What makes sintilimab a unique treatment option?
Sintilimab is recognized for its versatile applications across multiple cancer types, solidifying its importance in modern oncology.
How does fruquintinib contribute to cancer therapy?
Fruquintinib inhibits VEGF receptors, playing a crucial role in curbing tumor angiogenesis, which is vital for tumor growth.
What is Innovent's mission in biopharmaceuticals?
Innovent aims to develop and provide accessible, high-quality medicines to improve patient outcomes globally.
